Vivet Therapeutics Presents Three Posters on Cerebrotendinous Xanthomatosis Program and Novel AAV Gene Delivery Platform at European Society of Gene and Cell Therapy Annual Congress 2024
Paris, France, October 22, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, today announces the presentation of three posters demonstrating key pre-clinical findings for its gene therapy program, VTX-806 for the treatment of Cerebrotendinous Xanthomatosis (CTX), a study on S/MAR-containing AAV vector […]
Who’s excited about the @World Orphan Drug Congress Europe 2024🌍taking place in Spain from 22-25 October?
With over 25 years of expertise in #drugdevelopment, our Head of Clinical Operations & Patient Advocacy Representative, @Sonia Valero, will join industry leaders on a panel 📢 to share valuable insights on the “Convergence on Rare Disease and Precision Medicine – a Real Drive on Drug Development.” 📅 Date: Wednesday 23rd October 2024 🕘 Time: […]
🎓Are you attending the upcoming 2024 @European Society of Gene and Cell Therapy (#ESGCT) Congress, from 22-25 October in Rome, Italy?
Don’t miss the opportunity to meet the @Vivet Therapeutics leadership team who will be participating in a jam-packed schedule at the event. 👂Listen in as our Co-Founder and CSO, Dr @Gloria Gonzalez Aseguinolaza deliberates on the latest developments in gene therapy for liver disease in an oral presentation and panel discussion. Also check out our […]
🎉 25th Anniversary of the Spanish Society of Gene🧬& Cell🦠Therapy! 🎉
🎉 25th Anniversary of the Spanish Society of Gene🧬& Cell🦠Therapy! 🎉 Join our Co-Founder & Chief Scientific Officer, Dr @Gloria Gonzalez-Aseguinolaza in celebrating this special occasion at the @Fundacion Botín in Madrid, Spain from October 7– 8. Don’t miss the opportunity to hear insights from Gloria – a @Rosalind Franklin Society Special Award laureate and […]
📢2024 @Wilson Disease Association (WDA) Annual Conference in Charlotte, North Carolina from 4-6 October.
🤝Connect with @Sonia Valero, Head of Clinical Ops & Patient Advocacy Representative at @Vivet Therapeutics and US Patient Advocacy Consultant @Lori Mckenna, at the upcoming 📢2024 @Wilson Disease Association (WDA) Annual Conference in Charlotte, North Carolina from 4-6 October. At #Vivet, we are proud sponsors of the WDA Conference and believe patient engagement is crucial […]
Join our CEO, @Jean-Philippe Combal in the Big🍎Apple for @Chardan’s 8th Annual Genetic Medicines Conference!
Join our CEO, @Jean-Philippe Combal in the Big🍎Apple for @Chardan’s 8th Annual Genetic Medicines Conference! The premier event will bring together groundbreaking thought leaders to discuss major themes in genetic medicines through fireside chats, individual company presentations, one-on-one meetings, and panel discussions. Get in touch if you would like to connect with Jean-Philippe to learn […]
Leukodystrophy Awareness Month
📢 Leukodystrophy Awareness Month takes place throughout the whole month of September and is a time to raise awareness about these devastating rare conditions! Together 🤝 let’s shine a light💡 and increase understanding of leukodystrophy, a group of rare genetic metabolic disorders affecting the central nervous system. Leukodystrophies are characterized by the abnormal growth of […]
Vivet Therapeutics is a proud sponsor of the 2024 @European Society of Gene and Cell Therapy (#ESGCT)
Vivet Therapeutics is a proud sponsor of the 2024 @European Society of Gene and Cell Therapy (#ESGCT) meeting in Rome, Italy, from 22-25 October 🤝! 🔬 #ESGCT promotes basic and clinical research in #genetherapy, #celltherapy and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to […]
The @European Commission has granted Orphan Drug Designation (#ODD) to our gene therapy product, VTX-806, for the treatment of cerebrotendinous xanthomatosis (#CTX), a rare #neurodegenerativedisease in patients.
European Commission Grants Orphan Drug Designation for Vivet Therapeutics Gene Therapy Product for the Treatment of Cerebrotendinous Xanthomatosis (CTX) • Pre-clinical data of VTX-806 in mice demonstrated normalization of metabolic parameters in blood and brain, and of upregulated compensatory enzymes• EUR 4.9 million funding provided by French Government to develop VTX-806 as an effective treatment […]
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science
Paris, France, July 16, 2024 – Vivet Therapeutics (“Vivet”), a clinical stage biotech company developing novel and long-lasting gene therapies for rare inherited liver metabolic disorders, is delighted to announce that its Co-Founder & Chief Scientific Officer, Dr Gloria Gonzalez-Aseguinolaza, PhD, has been honored with the Rosalind Franklin Society (RFS) Special Award in Science given […]
